Possible role of PGRMC1 in breast cancer development

@article{Neubauer2013PossibleRO,
  title={Possible role of PGRMC1 in breast cancer development},
  author={Hans J Neubauer and Qianqian Ma and J. Zhou and Q T Yu and Xiangyan Ruan and Harald Seeger and Tanja N. Fehm and Alfred Otto Mueck},
  journal={Climacteric},
  year={2013},
  volume={16},
  pages={509 - 513}
}
Abstract Hormone therapy may increase the risk of breast cancer. Thus, especially the addition of synthetic progestins may play a decisive role according to the results of clinical studies. Overexpression of a special receptor, i.e. the progesterone receptor membrane component-1 (PGRMC1), may offer a potential new pathway to explain the observed increase in breast cancer risk in the combined arm of the Women's Health Initiative. PGRMC1 is expressed in breast cancer tissue and may be important… Expand
PGRMC1 Promotes Progestin-Dependent Proliferation of Breast Cancer Cells by Binding Prohibitins Resulting in Activation of ERα Signaling
Simple Summary Combined menopausal hormone therapy is associated with increased breast cancer risk in postmenopausal women. In our previous studies, progesterone receptor membrane component 1Expand
May progesterone receptor membrane component 1 (PGRMC1) predict the risk of breast cancer?
  • Y. Zhang, X. Ruan, +4 authors A. Mueck
  • Medicine
  • Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology
  • 2016
TLDR
It can be suggested that women with breast epithelium highly expressing PGRMC1 and in interaction with ERα may have an increased risk to develop breast cancer, especially when treated with hormone therapy. Expand
Medroxyprogesterone acetate-driven increase in breast cancer risk might be mediated via cross-talk with growth factors in the presence of progesterone receptor membrane component-1.
TLDR
A significant proliferative effect of MPA is demonstrated when combined with high concentrations of growth factors, more pronounced in breast cancer cells overexpressing PGRMC1. Expand
Micro-RNA-181a suppresses progestin-promoted breast cancer cell growth.
TLDR
Overexpression of miR-181a strongly reduced the cell viability of MCF-7 cells, mainly through increased apoptosis, which was evidenced by substantially increased gene expression of pro-apoptosis factors such as BAX and CASPASE 9 in miR -181a overexpressed cells. Expand
Progesterone receptor membrane component 1 deficiency attenuates growth while promoting chemosensitivity of human endometrial xenograft tumors.
TLDR
It is demonstrated that PGRMC1 plays a prominent role in the growth and chemoresistance of human endometrial tumors and promotes tumor cell viability during chemotherapeutic stress. Expand
High Level of Progesteron Receptor Membrane Component 1 (PGRMC 1) in Tissue of Breast Cancer Patients is Associated with Worse Response to Anthracycline-Based Neoadjuvant Therapy.
TLDR
It is demonstrated that PGRMC1 might play an important role in progression and therapy resistance of human breast tumors and could offer an interesting target for anticancer therapy. Expand
PGRMC1 in animal breast cancer tissue and blood is associated with increased tumor growth with norethisterone in contrast to progesterone and dydrogesterone: four-arm randomized placebo-controlled xenograft study
TLDR
An animal model was used to compare tumor growth using progesterone and its isomer dydrogesterone with norethisterone, which elicited in in vitro studies the strongest proliferating effect. Expand
Progesterone receptor membrane component 1 promotes the growth of breast cancers by altering the phosphoproteome and augmenting EGFR/PI3K/AKT signalling
TLDR
It is demonstrated that PGRMC1 plays a prominent role in regulating the growth of cancer cells by altering the PI3K/AKT/mTOR and EGFR signalling mechanisms in both ER-positive and TNBC cells. Expand
The presence of a membrane-bound progesterone receptor induces growth of breast cancer with norethisterone but not with progesterone: A xenograft model.
TLDR
This is the first comparison of both progestogens in vivo using nude mice, which are frequently used in xenograft models to determine whether women with overexpression of PGRMC1 are at increased risk of breast cancer if NET instead of progesterone is used in MHT. Expand
Identification of PGRMC1 as a Candidate Oncogene for Head and Neck Cancers and Its Involvement in Metabolic Activities
  • Yue Zhao, X. Ruan
  • Biology, Medicine
  • Frontiers in Bioengineering and Biotechnology
  • 2019
TLDR
In this work, the transcriptomics, genomics, and clinical data of 498 head-neck squamous cell carcinoma samples from the public-accessible database, The Cancer Genome Atlas, demonstrated that PGRMC1 expression served as a predictor for worse OS and the over-expression of P GRMC1 was strongly correlated with various metabolic process activity as well as cancer metastasis and cell proliferation features in human head- neck squamouscell carcinoma patient's cohort. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 61 REFERENCES
Progestogens and membrane-initiated effects on the proliferation of human breast cancer cells
TLDR
Some synthetic progestins trigger a proliferative response of PGRMC1-overexpressed MCF-7 cancer cells, and the effect of progestogens on breast cancer tumorigenesis may clearly depend on the specific pharmacology of the various synthetic progESTins. Expand
The presence of a membrane-bound progesterone receptor sensitizes the estradiol-induced effect on the proliferation of human breast cancer cells
TLDR
Overexpression of PGRMC1 sensitizes the proliferative response of the MCF-7 breast cancer cell line to estradiol, and the effect of progestogens on breast cancer tumorigenesis may depend on the specific progestogen used for hormone therapy or oral contraception. Expand
New insight on a possible mechanism of progestogens in terms of breast cancer risk
TLDR
Progesterone appears to act neutrally, whereas MPA, NET and DRSP trigger proliferation and thus might increase breast cancer risk, whereas PGRMC1 mediates a progestogen-dependent proliferative signal in MCF-7 cells. Expand
Overexpression of progesterone receptor membrane component 1: possible mechanism for increased breast cancer risk with norethisterone in hormone therapy
TLDR
The results suggest that undetected tumor cells overexpressing PGRMC1 may be more likely to develop into frank tumor cells in women undergoing E2/NET hormone therapy. Expand
Transcriptional analysis of novel hormone receptors PGRMC1 and PGRMC2 as potential biomarkers of breast adenocarcinoma staging.
TLDR
Measurements of PGRMC2 mRNA may be useful for distinguishing low stage tumors from higher stages that require more aggressive clinical management, and may be a useful test when tumor ER IHC results are equivocal. Expand
Membrane-initiated effects of progesterone on proliferation and activation of VEGF in breast cancer cells
  • H. Neubauer, G. Adam, +5 authors T. Fehm
  • Biology, Medicine
  • Climacteric : the journal of the International Menopause Society
  • 2009
TLDR
PGRMC1 is expressed in breast cancer tissue and mediates an RU-486-independent proliferative signal, which might also contribute to VEGF-induced neovascularization in tumor tissue. Expand
Elevated progesterone receptor membrane component 1/sigma‐2 receptor levels in lung tumors and plasma from lung cancer patients
TLDR
Levels in clinical tumor samples from squamous cell lung cancers and lung adenocarcinomas compared to corresponding nonmalignant tissue demonstrate that Pgrmc1 is a potential tumor and serum biomarker, as well as a therapeutic target, for lung cancer. Expand
Breast cancer proteomics reveals correlation between estrogen receptor status and differential phosphorylation of PGRMC1
TLDR
PGRMC1 phosphorylation may be involved in the clinical differences that underpin breast tumors of differing ER status, suggesting an altered keratin pool, and increased inflammation and wound responses in estrogen receptor negative tumors. Expand
Progestin-dependent progression of human breast tumor xenografts: a novel model for evaluating antitumor therapeutics.
TLDR
This study shows that xenografts obtained from BT-474 and T47-D human breast cancer cells without Matrigel in estrogen-supplemented nude mice begin to regress within days after tumor cell inoculation, but their growth is resumed if animals are supplemented with progesterone, suggesting a possible model system for screening potential therapeutic agents for their ability to prevent or inhibit progestin-dependent human breast tumors. Expand
Correction: Breast cancer proteomics reveals correlation between estrogen receptor status and differential phosphorylation of PGRMC1
Proteins significantly differentially abundant between estrogen receptor negative and estrogen receptor positive tumors at the 0.1% level were consistent with published profiles, suggesting anExpand
...
1
2
3
4
5
...